phenytoin has been researched along with fluconazole in 26 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (7.69) | 18.7374 |
1990's | 6 (23.08) | 18.2507 |
2000's | 6 (23.08) | 29.6817 |
2010's | 12 (46.15) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Duffy, EM; Jorgensen, WL | 1 |
Topliss, JG; Yoshida, F | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Campillo, NE; Guerra, A; Páez, JA | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Denning, DW; Graybill, JR; Hanson, LH; Pappagianis, D; Rinaldi, MG; Sharkey, PK; Stevens, DA; Tucker, RM | 1 |
Carey, D; Lee, HS; Tett, S | 1 |
Chandrasekar, PH; Edwards, DJ; Milad, MA; Touchette, MA | 1 |
Blum, RA; Gardner, MJ; Harrison, NJ; Henry, EB; Hilligoss, DM; Schentag, JJ; Wilton, JH | 1 |
Holland, JT; Mitchell, AS | 1 |
Howitt, KM; Oziemski, MA | 1 |
Cadle, RM; Hamill, RJ; Rodriguez-Barradas, MC; Zenon, GJ | 1 |
Bellati, U; Di Ilio, C; Giampietro, F; Iammarrone, E; Lamonaca, D; Tiboni, GM | 1 |
Angelucci, S; Bellati, U; Di Ilio, C; Giampietro, F; Moio, P; Tiboni, GM | 1 |
Brown, HS; Chadwick, A; Houston, JB | 1 |
Lai, Y; Li, N; Yuan, H | 1 |
Bergman, U; Bertilsson, L; Engström Hellgren, K; Helldén, A; Masquelier, M; Nilsson Remahl, I; Odar-Cederlöf, I; Ramsjö, M | 1 |
Gribakina, OG; Kolyvanov, GB; Novitskaia, IaG; Seredenin, SB; Smirnov, VV; Zherdev, VP | 1 |
2 review(s) available for phenytoin and fluconazole
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Fluconazole-induced symptomatic phenytoin toxicity.
Topics: Adult; AIDS-Related Opportunistic Infections; Animals; Drug Interactions; Fluconazole; Humans; Male; Middle Aged; Phenytoin; Seizures | 1994 |
3 trial(s) available for phenytoin and fluconazole
Article | Year |
---|---|
Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man.
Topics: Administration, Oral; Adult; Fluconazole; Humans; Ketoconazole; Male; Phenytoin; Random Allocation; Testosterone | 1992 |
Effect of fluconazole on the disposition of phenytoin.
Topics: Administration, Oral; Adult; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Interactions; Fluconazole; Humans; Infusions, Intravenous; Male; Phenytoin; Random Allocation | 1991 |
Teratological interaction between the bis-triazole antifungal agent fluconazole and the anticonvulsant drug phenytoin.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Antifungal Agents; Body Weight; Cleft Palate; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Synergism; Embryo Loss; Female; Fetal Death; Fetus; Fluconazole; Maternal-Fetal Exchange; Mice; Phenytoin; Pregnancy; Teratogens | 1999 |
21 other study(ies) available for phenytoin and fluconazole
Article | Year |
---|---|
Prediction of drug solubility from Monte Carlo simulations.
Topics: Monte Carlo Method; Pharmaceutical Preparations; Solubility | 2000 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations.
Topics: Adult; Aged; Antifungal Agents; Azoles; Carbamazepine; Coccidioides; Cryptococcus neoformans; Drug Interactions; Drug Therapy, Combination; Female; Fluconazole; Humans; Itraconazole; Ketoconazole; Malassezia; Male; Middle Aged; Mycoses; Phenytoin; Rifampin | 1992 |
Drug interactions with fluconazole.
Topics: Cross-Sectional Studies; Cyclosporine; Drug Interactions; Fluconazole; Humans; Phenytoin; Theophylline; Warfarin | 1992 |
Fluconazole and phenytoin: a predictable interaction.
Topics: Antifungal Agents; Drug Interactions; Fluconazole; Humans; Middle Aged; Phenytoin; Triazoles | 1989 |
Phenytoin toxicity induced by fluconazole.
Topics: Adult; Drug Interactions; Female; Fluconazole; Humans; Nystagmus, Pathologic; Phenytoin; Reflex, Abnormal | 1989 |
Additional investigation on the potentiation of phenytoin teratogenicity by fluconazole.
Topics: Animals; Chromatography, High Pressure Liquid; Cleft Palate; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluconazole; Injections, Intraperitoneal; Male; Maternal-Fetal Exchange; Mice; Mice, Inbred ICR; Phenytoin; Placenta; Pregnancy; Prenatal Exposure Delayed Effects; Teratogens | 2003 |
Use of isolated hepatocyte preparations for cytochrome P450 inhibition studies: comparison with microsomes for Ki determination.
Topics: Animals; Catalysis; Cells, Cultured; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Enzyme Inhibitors; Fluconazole; Fluoxetine; Fluvoxamine; Hepatocytes; Ketoconazole; Kinetics; Male; Miconazole; Microsomes, Liver; Midazolam; Phenytoin; Quinine; Rats; Rats, Sprague-Dawley; Tolbutamide | 2007 |
Evaluation of in vitro models for screening alkaline phosphatase-mediated bioconversion of phosphate ester prodrugs.
Topics: Alkaline Phosphatase; Animals; Caco-2 Cells; Drug Delivery Systems; Drug Stability; Fluconazole; Half-Life; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Intestines; Male; Mucous Membrane; Organophosphates; Phenytoin; Phosphates; Prodrugs; Rats; Rats, Sprague-Dawley; Solubility | 2009 |
Fluconazole-induced intoxication with phenytoin in a patient with ultra-high activity of CYP2C9.
Topics: Alleles; Angiotensin II Type 1 Receptor Blockers; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Ataxia; Behcet Syndrome; Case-Control Studies; Cytochrome P-450 CYP2C9; Cytochrome P-450 Enzyme System; Disorders of Excessive Somnolence; Dose-Response Relationship, Drug; Fatigue; Female; Fluconazole; Humans; Losartan; Middle Aged; Pharmaceutical Preparations; Phenotype; Phenytoin; Polymorphism, Genetic; Speech Intelligibility; Warfarin | 2010 |
[In vivo evaluation of the metabolic ratio of CYP2C9 and CYP1A2 drug markers after administration of afobazole in comparison to standard inducers and inhibitors of cytochromes].
Topics: Animals; Anti-Anxiety Agents; Anti-Bacterial Agents; Anticonvulsants; Antifungal Agents; Benzimidazoles; Ciprofloxacin; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme System; Cytochromes; Enzyme Induction; Enzyme Inhibitors; Fluconazole; Male; Morpholines; Phenytoin; Rats; Rifampin | 2013 |